RHJA
AVNS

Rice Hall James & Associates’s Avanos Medical AVNS Stock Holding History

Rice Hall James & Associates’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-118,346
Closed -$1.45M – 250
2025
Q2 		$1.45M Sell
118,346
-9,713
-8% -$122K 0.08% 185
2025
Q1 		$1.84M Buy
128,059
+65,930
+106% +$1.03M 0.11% 166
2024
Q4 		$989K Buy
+62,129
New +$1.23M 0.05% 206
2020
Q1 		– Sell
-405,663
Closed -$13.7M – 263
2019
Q4 		$13.7M Sell
405,663
-12,019
-3% -$435K 0.46% 88
2019
Q3 		$15.6M Sell
417,682
-27,291
-6% -$1.04M 0.56% 72
2019
Q2 		$19.4M Buy
444,973
+64,967
+17% +$2.78M 0.64% 50
2019
Q1 		$16.2M Buy
+380,006
New +$17M 0.52% 68

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Rice Hall James & Associates's AVNS Position: Q3 2025 in Review

Rice Hall James & Associates sold out of Avanos Medical (AVNS) in Q3 2025, closing a stake of 118,346 shares — an estimated $1.45M sold.

Rice Hall James & Associates first reported a position in AVNS in Q1 2019 and held it in 7 quarters. The position peaked at $19.4M in Q2 2019. 276 funds tracked by Wall St. Rank hold AVNS as of Q3 2025.

  • Rice Hall James & Associates reported no remaining Avanos Medical position as of Q3 2025 after selling out during the quarter.
  • Rice Hall James & Associates sold 118,346 Avanos Medical shares in Q3 2025, an estimated $1.45M.
  • Rice Hall James & Associates first reported a position in Avanos Medical in Q1 2019 and held it in 7 quarters.
  • Rice Hall James & Associates's Avanos Medical position peaked at $19.4M in Q2 2019.
  • 276 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2025.

Based on Rice Hall James & Associates's 13F filing for Q3 2025, filed 16 Oct 2025.